These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

478 related articles for article (PubMed ID: 28982112)

  • 1. Lymph node metastases in resected pancreatic ductal adenocarcinoma: predictors of disease recurrence and survival.
    Morales-Oyarvide V; Rubinson DA; Dunne RF; Kozak MM; Bui JL; Yuan C; Qian ZR; Babic A; Da Silva A; Nowak JA; Khalaf N; Brais LK; Welch MW; Zellers CL; Ng K; Chang DT; Miksad RA; Bullock AJ; Tseng JF; Swanson RS; Clancy TE; Linehan DC; Findeis-Hosey JJ; Doyle LA; Hornick JL; Ogino S; Fuchs CS; Hezel AF; Koong AC; Wolpin BM
    Br J Cancer; 2017 Dec; 117(12):1874-1882. PubMed ID: 28982112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer.
    Riediger H; Keck T; Wellner U; zur Hausen A; Adam U; Hopt UT; Makowiec F
    J Gastrointest Surg; 2009 Jul; 13(7):1337-44. PubMed ID: 19418101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymph node ratio as valuable predictor in pancreatic cancer treated with R0 resection and adjuvant treatment.
    You MS; Lee SH; Choi YH; Shin BS; Paik WH; Ryu JK; Kim YT; Jang DK; Lee JK; Kwon W; Jang JY; Kim SW
    BMC Cancer; 2019 Oct; 19(1):952. PubMed ID: 31615457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Comprehensive Assessment of Accurate Lymph Node Staging and Preoperative Detection in Resected Pancreatic Cancer.
    Masuda T; Dann AM; Elliott IA; Baba H; Kim S; Sedarat A; Muthusamy VR; Girgis MD; Joe Hines O; Reber HA; Donahue TR
    J Gastrointest Surg; 2018 Feb; 22(2):295-302. PubMed ID: 29043580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lymph Node Metastatic Patterns and Survival Predictors Based on Tumor Size in Pancreatic Ductal Adenocarcinoma.
    Pu N; Chen Q; Gan W; Shen Y; Gao S; Habib JR; Yin H; Zhang J; Kinny-Köster B; Cui M; Li J; Dong Y; Nagai M; Liu L; Yu J; Wu W; Lou W
    Adv Ther; 2021 Aug; 38(8):4258-4270. PubMed ID: 34176089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Superior Mesenteric Artery Margin of Posttherapy Pancreaticoduodenectomy and Prognosis in Patients With Pancreatic Ductal Adenocarcinoma.
    Liu L; Katz MH; Lee SM; Fischer LK; Prakash L; Parker N; Wang H; Varadhachary GR; Wolff RA; Lee JE; Pisters PW; Maitra A; Fleming JB; Estrella J; Rashid A; Wang H
    Am J Surg Pathol; 2015 Oct; 39(10):1395-403. PubMed ID: 26200098
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical Implications of Extensive Lymph Node Metastases for Resected Pancreatic Cancer.
    Lowder CY; Metkus J; Epstein J; Kozak GM; Lavu H; Yeo CJ; Winter JM
    Ann Surg Oncol; 2018 Dec; 25(13):4004-4011. PubMed ID: 30225835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prognostic value of different node staging systems in patients with ≤15 lymph nodes following surgery for gastric adenocarcinoma.
    Kılıç MÖ; Gündoğdu SB; Özden S; Saylam B; Tez M
    Acta Chir Belg; 2018 Feb; 118(1):1-6. PubMed ID: 28669280
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adenocarcinoma of the pancreas: Does prognosis depend on mode of lymph node invasion?
    Buc E; Couvelard A; Kwiatkowski F; Dokmak S; Ruszniewski P; Hammel P; Belghiti J; Sauvanet A
    Eur J Surg Oncol; 2014 Nov; 40(11):1578-85. PubMed ID: 24923739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of the American Joint Committee on Cancer 8th edition staging system for the pancreatic ductal adenocarcinoma.
    Shin DW; Lee JC; Kim J; Woo SM; Lee WJ; Han SS; Park SJ; Choi KS; Cha HS; Yoon YS; Han HS; Hong EK; Hwang JH
    Eur J Surg Oncol; 2019 Nov; 45(11):2159-2165. PubMed ID: 31202572
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Revisiting the concept of lymph node metastases of pancreatic head cancer: number of metastatic lymph nodes and lymph node ratio according to N stage.
    Kang MJ; Jang JY; Chang YR; Kwon W; Jung W; Kim SW
    Ann Surg Oncol; 2014 May; 21(5):1545-51. PubMed ID: 24419758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic assessment of different lymph node staging methods for pancreatic cancer with R0 resection: pN staging, lymph node ratio, log odds of positive lymph nodes.
    La Torre M; Nigri G; Petrucciani N; Cavallini M; Aurello P; Cosenza G; Balducci G; Ziparo V; Ramacciato G
    Pancreatology; 2014; 14(4):289-94. PubMed ID: 25062879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T-Helper 1 Immune Response in Metastatic Lymph Nodes of Pancreatic Ductal Adenocarcinoma: A Marker For Prolonged Survival.
    Nizri E; Sternbach N; Bar-David S; Ben-Yehuda A; Gerstenhaber F; Ofir T; Wolf I; Weiner G; Lahat G; Klausner J
    Ann Surg Oncol; 2018 Feb; 25(2):475-481. PubMed ID: 29124488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Redefining the R1 resection for pancreatic ductal adenocarcinoma: tumour lymph nodal burden and lymph node ratio are the only prognostic factors associated with survival.
    John BJ; Naik P; Ironside A; Davidson BR; Fusai G; Gillmore R; Watkins J; Rahman SH
    HPB (Oxford); 2013 Sep; 15(9):674-80. PubMed ID: 23458477
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reappraisal of nodal staging and study of lymph node station involvement in distal pancreatectomy for body-tail pancreatic ductal adenocarcinoma.
    Malleo G; Maggino L; Nobile S; Casciani F; Cacciatori N; Paiella S; Luchini C; Rusev B; Capelli P; Marchegiani G; Bassi C; Salvia R
    Eur J Surg Oncol; 2020 Sep; 46(9):1734-1741. PubMed ID: 32327367
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lymph node involvement beyond peripancreatic region in pancreatic head cancers: when results belie expectations.
    Golse N; Lebeau R; Lombard-Bohas C; Hervieu V; Ponchon T; Adham M
    Pancreas; 2013 Mar; 42(2):239-48. PubMed ID: 23038054
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Single-Institution Validation Study of Lymph Node Staging By the AJCC 8th Edition for Patients with Pancreatic Head Cancer: A Proposal to Subdivide the N2 Category.
    Asano D; Nara S; Kishi Y; Esaki M; Hiraoka N; Tanabe M; Shimada K
    Ann Surg Oncol; 2019 Jul; 26(7):2112-2120. PubMed ID: 31037440
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pancreatic cancer patients with lymph node involvement by direct tumor extension have similar survival to those with node-negative disease.
    Williams JL; Nguyen AH; Rochefort M; Muthusamy VR; Wainberg ZA; Dawson DW; Tomlinson JS; Hines OJ; Reber HA; Donahue TR
    J Surg Oncol; 2015 Sep; 112(4):396-402. PubMed ID: 26303811
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The number and ratio of positive lymph nodes affect pancreatic cancer patient survival after neoadjuvant therapy and pancreaticoduodenectomy.
    Fischer LK; Katz MH; Lee SM; Liu L; Wang H; Varadhachary GR; Wolff RA; Lee JE; Maitra A; Roland CL; Fleming JB; Estrella J; Rashid A; Wang H
    Histopathology; 2016 Jan; 68(2):210-20. PubMed ID: 25945396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The efficacy of adjuvant therapy for pancreatic invasive intraductal papillary mucinous neoplasm (IPMN).
    McMillan MT; Lewis RS; Drebin JA; Teitelbaum UR; Lee MK; Roses RE; Fraker DL; Vollmer CM
    Cancer; 2016 Feb; 122(4):521-33. PubMed ID: 26587698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.